Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arbutus Biopharma Corp (ABUS) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Arbutus Biopharma Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1447028.
Total stock buying since 2015: $6,950.
Total stock sales since 2015: $2,450,823.
Total stock option exercises since 2015: $183,960.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 76,654 | $251,653 | 0 | $0 |
| 2024 | 0 | $0 | 42,943 | $111,506 | 54,915 | $30,752 |
| 2021 | 0 | $0 | 220,000 | $1,118,000 | 0 | $0 |
| 2020 | 0 | $0 | 60,000 | $300,280 | 0 | $0 |
| 2018 | 0 | $0 | 54,250 | $477,994 | 52,007 | $43,310 |
| 2017 | 0 | $0 | 40,000 | $191,390 | 0 | $0 |
| 2016 | 0 | $0 | 0 | $0 | 14,178 | $4,905 |
| 2015 | 1,000 | $6,950 | 0 | $0 | 236,472 | $104,993 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-02 | 0 | $0 | 76,654 | $251,653 | 0 | $0 |
| 2024-08 | 0 | $0 | 8,846 | $32,641 | 54,915 | $30,752 |
| 2024-02 | 0 | $0 | 34,097 | $78,865 | 0 | $0 |
| 2021-12 | 0 | $0 | 200,000 | $1,018,000 | 0 | $0 |
| 2021-02 | 0 | $0 | 20,000 | $100,000 | 0 | $0 |
| 2020-12 | 0 | $0 | 40,000 | $200,080 | 0 | $0 |
| 2020-07 | 0 | $0 | 20,000 | $100,200 | 0 | $0 |
| 2018-11 | 0 | $0 | 0 | $0 | 25,000 | $33,750 |
| 2018-08 | 0 | $0 | 4,250 | $40,434 | 0 | $0 |
| 2018-07 | 0 | $0 | 50,000 | $437,560 | 0 | $0 |
| 2018-04 | 0 | $0 | 0 | $0 | 27,007 | $9,560 |
| 2017-10 | 0 | $0 | 10,000 | $80,000 | 0 | $0 |
| 2017-08 | 0 | $0 | 30,000 | $111,390 | 0 | $0 |
| 2016-08 | 0 | $0 | 0 | $0 | 14,178 | $4,905 |
| 2015-09 | 0 | $0 | 0 | $0 | 236,472 | $104,993 |
| 2015-08 | 1,000 | $6,950 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-04 | Sims Karen (Chief Medical Officer) | Sale | 19,348 | 3.28 | 63,519 |
| 2025-02-04 | Mcelhaugh Michael J. (Interim President & CEO) | Sale | 23,790 | 3.28 | 78,102 |
| 2025-02-04 | Naftzger J. Christopher (General Counsel and CCO) | Sale | 11,333 | 3.28 | 37,206 |
| 2025-02-04 | Hastings David C (Chief Financial Officer) | Sale | 22,183 | 3.28 | 72,826 |
| 2024-08-14 | Manchester Keith S (Director) | Sale | 8,846 | 3.69 | 32,641 |
| 2024-08-14 | Manchester Keith S (Director) | Option Ex | 54,915 | .56 | 30,752 |
| 2024-02-02 | Sims Karen (Chief Medical Officer) | Sale | 4,358 | 2.31 | 10,080 |
| 2024-02-02 | Mcelhaugh Michael J. (Interim President & CEO) | Sale | 10,164 | 2.31 | 23,509 |
| 2024-02-02 | Sofia Michael J. (Chief Scientific Officer) | Sale | 9,982 | 2.31 | 23,088 |
| 2024-02-02 | Hastings David C (Chief Financial Officer) | Sale | 9,593 | 2.31 | 22,188 |
| 2021-12-01 | Sofia Michael J. (Chief Scientific Officer) | Sale | 200,000 | 5.09 | 1,018,000 |
| 2021-02-09 | Mcelhaugh Michael J. (Chief Business Officer) | Sale | 20,000 | 5.00 | 100,000 |
| 2020-12-14 | Mcelhaugh Michael J. (Chief Business Officer) | Sale | 40,000 | 5.00 | 200,080 |
| 2020-07-23 | Mcelhaugh Michael J. (Chief Business Officer) | Sale | 20,000 | 5.01 | 100,200 |
| 2018-11-28 | Murray Mark J. (Director) | Option Ex | 25,000 | 1.35 | 33,750 |
| 2018-08-13 | Sofia Michael J. (Chief Scientific Officer) | Sale | 4,250 | 9.51 | 40,434 |
| 2018-07-11 | Sofia Michael J. (Chief Scientific Officer) | Sale | 10,000 | 10.00 | 100,000 |
| 2018-07-09 | Sofia Michael J. (Chief Scientific Officer) | Sale | 10,000 | 8.91 | 89,060 |
| 2018-07-06 | Sofia Michael J. (Chief Scientific Officer) | Sale | 10,000 | 8.45 | 84,500 |
| 2018-07-05 | Sofia Michael J. (Chief Scientific Officer) | Sale | 10,000 | 8.40 | 84,000 |
| 2018-07-03 | Sofia Michael J. (Chief Scientific Officer) | Sale | 10,000 | 8.00 | 80,000 |
| 2018-04-17 | Murray Mark J. (President & CEO) | Option Ex | 27,007 | .35 | 9,560 |
| 2017-10-03 | Sofia Michael J. (Chief Scientific Officer) | Sale | 10,000 | 8.00 | 80,000 |
| 2017-08-15 | Sofia Michael J. (Chief Scientific Officer) | Sale | 30,000 | 3.71 | 111,390 |
| 2016-08-16 | Abrams Michael J. (Managing Director) | Option Ex | 14,178 | .35 | 4,905 |
| 2015-09-11 | Murray Mark J. (President & CEO) | Option Ex | 219,428 | .44 | 97,426 |
| 2015-09-11 | Abrams Michael J. (Managing Director) | Option Ex | 17,044 | .44 | 7,567 |
| 2015-08-24 | Henriques Richard C Jr | Buy | 1,000 | 6.95 | 6,950 |
Insider trading activities including stock purchases, stock sales, and option exercises of ABUS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Arbutus Biopharma Corp (symbol ABUS, CIK number 1447028) see the Securities and Exchange Commission (SEC) website.